Clinical trials: Elderly Infection
Influenza, Human
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season.
- Trial name
- NCT07805707
- Testing
- mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine
- Where
- 163 sites in United States
- Volunteers
- 54,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Enterovirus Infections
A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old
The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant AlPO4 at 0.5-μg, 1-μg, 2-μg and 5-μg dose (if required) in children…
- Trial name
- NCT02777411
- Testing
- EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose), EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose), EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)
- Where
- 4 sites in Taiwan
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Enimmune Corporation
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Children Aged 2-17 Years
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years.
- Trial name
- NCT06550830
- Testing
- Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13®
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Staphylococcal Infections
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag).
- Trial name
- NCT01364571
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 16 sites in United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Pfizer
Candidiasis, Candidemia
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT00739934
- Testing
- voriconazole (Vfend)
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.
- Trial name
- NCT01051661
- Testing
- GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
- Where
- 17 sites in Australia, Brazil and 6 more
- Volunteers
- 6,154 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccine
A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
The purpose of this study is to confirm the safety until Day 29 after injection of a single dose of quadrivalent vaccine ASP7374 in adult subjects aged 20 or older
- Trial name
- NCT02366962
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Pneumonia, Respiratory Tract Diseases
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
Infections with Streptococcus pneumoniae often cause serious health problems, especially for infants and the elderly.Failure to cover all polysaccharide types is an even greater problem with adults than with children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- PⅠCTPV (NCT04087460)
- Testing
- Protein based pneumococcal vaccine(Low dose), Protein based pneumococcal vaccine(Middle dose), Protein based pneumococcal vaccine(High dose)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Poliomyelitis
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60~89 days).
- Trial name
- NCT07297186
- Testing
- sIPV, wIPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
SARS-CoV-2
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
- Trial name
- BabyCOVE (NCT05584202)
- Testing
- mRNA-1273.214
- Where
- 39 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
RSV Infection, hMPV
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
- Trial name
- NCT06583031
- Testing
- RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3
- Where
- 6 sites in Australia
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and…
- Trial name
- NCT02214225
- Testing
- Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
- Where
- 33 sites in United States
- Volunteers
- 3,484 people, healthy volunteers welcome
- Sponsor
- Seqirus
Rotavirus Infection, Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants
Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™
This study aims to test the clinical samples (stool and serum) previously collected during clinical development of HRV vaccine, to identify if there is any evidence of PCV-1 replication and/or immune response to the PCV-1 in…
- Trial name
- NCT01511133
- Testing
- Stool sample, Serum sample
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386113
- Testing
- Fluarix and adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Tuberculosis
A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine…
- Trial name
- NCT06732583
- Testing
- Tuberculosis (TB) vaccine (Ad5-105K), Ad5-105K
- Where
- Indonesia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19 Vaccine) and determine the recommended dose in Japanese healthy adults and elderly participants.
- Trial name
- NCT04821674
- Testing
- DS-5670a
- Where
- Japan
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Influenza, Human
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04576702
- Testing
- Investigational aIIV4c, IIV4c, aIIV4
- Where
- 21 sites in United States
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Seqirus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.